EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Are We Ready With Prevention for Type 1 Diabetes?

Evelina Maines, Roberto Franceschi iD, Francesca di Candia, Enza Mozzillo

Diabetes/Metabolism Research and Reviews · 2025-10 · 41 (7)

DOI: 10.1002/dmrr.70101 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 25.10.2025. Verfasst von Evelina Maines und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, S. Chiara Hospital of Trento, APSS, Trento, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Definitive prevention for type 1 diabetes (T1D) is not yet available, but we are now entering a new era where disease‐modifying therapies are becoming available in T1D to halt disease progression. In this review, we present up‐to‐date knowledge related to the prevention of T1D in youth, involving disease‐modifying therapies at different T1D stages. A narrative literature review utilising the PubMed/MEDLINE database was performed using the keywords ‘screening’, ‘prevention’, ‘Disease‐modifying therapy’, and ‘Diabetes Mellitus, Type 1’ [Mesh] in youth aged 0–18 years. Only teplizumab has been approved by the FDA as the first drug shown to delay the onset of Stage 3 T1D. Other monoclonal antibodies targeting specific immune cells, agents targeting specific cytokines, antigen‐specific therapies, and immunomodulant and/or immunosuppressive agents have been studied alone or in combination to control or delay the progression of beta‐cell destruction. In individuals with Stage 3 T1D, several intervention trials have led to a temporary improvement in beta‐cell function, but this benefit has consistently been short‐lived. Ongoing and future research will be essential to refine patient selection, identify additional therapeutic targets, and optimise the timing and durability of immunotherapy responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansChildAdolescentDisease ProgressionImmunotherapy

Stichwörter der Autor:innen

childrenpreventionreviewscreeningtype 1 diabetes

Autor:innen und Institutionen

  • Department of Pediatrics, S. Chiara Hospital of Trento, APSS, Trento, Italy.
  • CISMed-Centro Interdipartimentale di Scienze Mediche, University of Trento, Trento, Italy.
  • Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Roberto Franceschi

Zitieren

APA

Maines, E., Franceschi, R., Candia, F. D., & Mozzillo, E. (2025). Are We Ready With Prevention for Type 1 Diabetes?. Diabetes/Metabolism Research and Reviews, 41(7). https://doi.org/10.1002/dmrr.70101

Vancouver

Maines E, Franceschi R, Candia FD, Mozzillo E. Are We Ready With Prevention for Type 1 Diabetes?. Diabetes/Metabolism Research and Reviews. 2025;41(7). doi:10.1002/dmrr.70101

BibTeX
@article{Maines2025,
  author = {Maines, Evelina and Franceschi, Roberto and Candia, Francesca di and Mozzillo, Enza},
  title = {Are We Ready With Prevention for Type 1 Diabetes?},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  volume = {41},
  number = {7},
  doi = {10.1002/dmrr.70101}
}
Kostenlos starten →